A New Therapeutic Target for Myelofibrosis is Cause for Gli
In a new study, researchers report that Gli1+ mesenchymal stromal cells play a central role in bone marrow fibrosis development and represent a new therapeutic target. After first confirming that murine and human BM Gli1+ cells are of MSC-origin, genetic fate-tracing in two murine PMF models showed that Gli1+ cells are mobilized from perivascular and endosteal niches by the malignant hematopoietic clone to become myofibroblasts.
Sci Transl Med
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology